Spyre Therapeutics (SYRE)
What the price implies
A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.
Fundamental grade
Five factors scored 1 to 9 from SYRE's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.
Key numbers
Results from SEC filings
Fiscal years, from Spyre Therapeutics's 10-K filings. The deep dive has 15+ years, quarters and every line.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $19M | $2M | $886,000 | $0 | $0 |
| Net income | -$66M | -$84M | -$339M | -$208M | -$155M |
| Free cash flow | -$54M | -$80M | -$100M | -$157M | — |
| EPS (diluted) | -$25.02 | -$24.86 | $13.76 | — | — |
| Operating margin | -350.3% | -3640.2% | -27348.0% | — | — |
Superinvestors who own SYRE
From each investor's latest 13F filing (what a 13F shows). 1 of the investors we track hold it.
| Investor | Last quarter | Value | % of portfolio | Quarter |
|---|---|---|---|---|
| Cliff Asness AQR Capital Management |
Added | $2M | 0.00% | Q2 2026 |
Insider buying
Open-market purchases by Spyre Therapeutics's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.
Get an alert at your buy price
Pick the price you'd be interested at. We'll email you when SYRE trades at or below it.
Free accounts get 3 price alerts. No card needed.
In the full deep dive
Questions
Are Spyre Therapeutics insiders buying the stock?
No open-market insider purchases of SYRE in the last 12 months, according to SEC Form 4 filings.
Which superinvestors own Spyre Therapeutics?
1 of the superinvestors Investingly tracks hold SYRE in their latest 13F, including Cliff Asness.
Prices and ratios as of Oct 7, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.